Luckwel Pharmaceuticals Inc.
LWEL
Other OTC3.50
USD
- -
- -
Luckwel Pharmaceuticals Inc.
LWEL
(Other OTC)
Recent
price
3.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Luckwel Pharmaceuticals Inc. (OTC: LWEL) operates as a specialty pharmaceutical company focused on the acquisition, development, manufacture, and commercialization of innovative therapies targeting autoimmune diseases, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), and infectious diseases; its pipeline includes LWEL-2120 for rheumatoid arthritis, LWEL-2119 for HIV, and LWEL-2103 for COVID-19. The company, founded in 2013 and headquartered in Cambridge, Massachusetts, maintains a lean structure with one employee and limited current operations as a development-stage entity. In April 2018, Luckwel changed its name from Luckycom Pharmaceuticals Inc. to reflect its sharpened focus on pharmaceutical innovation, marking its most recent significant reorganization with no major acquisitions, partnerships, funding rounds, or new product launches reported in the last two years.